85598-13-6

Usage

Uses

Used in Pharmaceutical Industry:
1-Bromo-4-methoxy-2-methyl-3-nitrobenzene is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 1-Bromo-4-methoxy-2-methyl-3-nitrobenzene is utilized as a precursor in the synthesis of agrochemicals, aiding in the production of pesticides and other agricultural chemicals.
Used in Dye Industry:
1-Bromo-4-methoxy-2-methyl-3-nitrobenzene is employed as a starting material in the synthesis of dyes, playing a role in the creation of colorants for various applications.
Used in Chemical Intermediates:
As an intermediate in chemical manufacturing, 1-Bromo-4-methoxy-2-methyl-3-nitrobenzene is used to produce a range of other chemicals, expanding its utility across different chemical processes.

Upstream product

• 85598-12-5 4-bromo-3-methyl-2-nitro-phenol 
• 74-88-4 methyl iodide 
• 108-39-4 3-methyl-phenol 
• 5345-42-6 1-methoxy-3-methyl-2-nitro-benzene 
• 27060-75-9 4-bromo-3-methylanisole 
• 4920-77-8 3-methyl-2-nitrophenol 

Downstream Products

• 786596-55-2 2-Methyl-3-bromo-6-methoxyaniline 
• 436091-59-7 4-bromo-7-methoxy-1H-indole 
• 1186421-69-1 3-[3-(7-methoxy-1H-indazol-4-yl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethylbenzenesulfonamide 
• 1186422-15-0 7-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 938062-01-2 4-bromo-7-methoxy-1H-indazole 
• 85598-14-7 2-Nitro-3-methyl-4-cyanoanisole 
• 1400276-22-3 C₁₄H₈Br₂FNO 
• 1400276-20-1 C₁₅H₁₀Br₂FNO 
• 1400275-73-1 dimethyl (pyrrolo[3,2,1-kl]phenoxazine-3,8-diylbis{1H-imidazole-5,2-diyl(2S)pyrrolidine-2,1-diyl[(1R)-2-oxo-1-phenylethane-2,1-diyl]})biscarbamate 
• 1400276-09-6 C₁₄H₈Br₂FNO 
• 1400276-07-4 C₁₅H₁₀Br₂FNO 
• 1333378-11-2 C₄₁H₃₅BrN₈O₆S₂ 
• 1333378-12-3 C₃₁H₃₁N₇O₄S₂ 
• 1333378-30-5 C₃₆H₃₉N₇O₆S₂ 

Relevant academic research and scientific papers

AURORA AND FLT3 KINASES MODULATORS

The invention provides a compound having the formula (1): and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer.

QUINAZOLINE COMPOUNDS

The present invention relates to quinazoline compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, R3, R4, R5, R6 and R7 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

AURORA AND FLT3 KINASES MODULATORS

The invention provides a compound having the formula (1) useful as modulator of the activity of Aurora kinases and FLT3 kinases: and salts thereof; wherein: R1 is hydrogen or C1-2 alkyl; and R2, R3 and R4 are the same or different and each is selected from hydrogen, C1-2 alkyl, fluorine, chlorine, C1-2 alkoxy and trifluoromethyl, provided that no more than two of R2, R3 and R4 are other than hydrogen. Also provided are pharmaceutical compositions containing the compounds and their use in medicine, and in particular in the treatment of cancer

TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.

TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses tetracyclic xanthene derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b, and R2 are as defined herein. The present invention also discloses compositions comprising at least one tetracyclic xanthene derivative, and methods of using the tetracyclic xanthene derivatives for treating or preventing HCV infection in a patient.

Abnormal reactions of 2-methoxy-4,9-dimethyl-1-nitroacridine with selenous acid and selenium(IV) oxide. Synthesis of 1H-selenopheno[2,3,4-k,l]acridine-1- one: A new seleno-containing ring system

Unusual course of the reaction was revealed on the oxidation of functionally substituted acridine containing the activated methyl groups by well-known oxidants, such as selenous acid and selenium(IV) oxide. Treatment of 2-methoxy-4,9-dimethyl-1-nitroacridine (5) with an excess of H 2SeO3 in boiling ethanol gave a mixture of the normal reaction products, 2-methoxy-4-methyl-1-nitro-9-formylacridine (11) (isolated yield 29%) and 2-methoxy-4-methyl-1-nitroacridine-9-carboxylic acid (12) (36%), together with an abnormal product, 3-methoxy-5-methyl-1H-selenopheno[2,3,4-k,l] acridine-1-one (13) (21%), which is the first example of a new seleno-containing ring system. With the use of SeO2 the yield of selenolactone 13 was much lower.

PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Phenylsulfonamide substituted, pyrazolo[1,5-a]pyrimidines are described. The compounds of the invention selectively inhibit Raf kinase activity and are useful for treating disorders associated with Raf kinases. Formula (I)

INDOLES AS 5-HT6 MODULATORS

The present invention relates to novel compounds of formula (I) wherein m, n, R0, R1, R2, R3 and R4 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for t

Enantioselective synthesis of the aminoimidazole segment of dragmacidin D

A facile enantioselective synthesis of the 2-aminoimidazole side-chain of dragmacidin D has been developed, which involved the regio- and stereoselective opening of the chiral epoxide 9 by a diindolylcuprate reagent, followed by further steps to give 5-substituted N-(1H-imidazol-2-yl)acetamide 2.